Ht Biological Medicine Company Financing Problems And Countermeasures Research

Biomedical industry is a strategic emerging industry and supported and developed by China. It is of great significant of the transformation of economic growth mode, promoting the quality of economic growth, protecting people’s health and the construction of an innovative country. Biological pharmaceutical enterprises have "three high and one long" Characteristics which is high investment, high risk, high yield and long cycle. It is these characteristics which urgent demand for large capital. On the other hand, our biology pharmaceutical industry started later, which leads to the enterprise’s management no-standard and our financial environment immature. The current financial environment can not service small and medium-sized pharmaceutical enterprises smoothly. So it is hard for the small and medium-sized biology pharmaceutical enterprises to growth without huge money. Investigating the financing problems and measures of small and medium-sized bio-pharmaceutical enterprises will help to resolve their financing problems and promote the innovation and development of China’s pharmaceutical industryThe paper is based on the HT pharmaceutical enterprise which is a small and medium-sized pharmaceutical enterprise, the funds needs and current financial modes of HT were discussed to find out the financing gap and the reason for gap. It is analyses by SWOT, combined with the international and domestic pharmaceutical Enterprises and HT biological pharmaceutical company’s advantages and disadvantages. Some financing measures were taken to improve HT biological pharmaceutical company financing shortage problems. The Innovation of this paper is hope to external publicity, strengthen international exchanges and cooperation in order to attract venture capital firms; to make full use of the favorable policies of national and local biomedical strategic emerging industries to actively apply for government funds; to standardize enterprise internal management for expansion of internal funds; or to use intangible assets for the mortgage, such as:patent or new drug certificate for a mortgage.This paper includes six parts, part1mainly introduces the paper’s goals, background and the significance, as well as the current status of the research in domestic and abroad and the structure of this article. In part2, HT pharmaceutical enterprise’s funds demands are analyses. In part3, it is described the current financing mode of HT biological pharmaceutical company, the financing gap and the reason for gap. In part4, it is analyses by SWOT, combined with the international biological pharmaceutical environment and the advantage and disadvantage of HT biological pharmaceutical company’s SWOT. In part5, some measures are taken to improve the HT biological pharmaceutical company capital shortage problem. In part6, the deficiencies and the prospects for the future of the article are described.